The AlphaVax pipeline is targeting pandemic influenza and cytomegalovirus (CMV), as well as grant and collaborator-supported programs in HIV, prostate and breast cancer, and several biodefense vaccines. Clinical data from the first alphavaccine human trials have confirmed safety and immunological activity in man. These immune responses are characterized as robust and balanced antibody (B-cell) and cellular (T-cell) immune responses, confirming the promising data we have obtained in over a decade of intensive pre-clinical work with this vector platform.
View Top Employees from AlphaVax| Website | http://www.alphavax.com |
| Revenue | $24 million |
| Funding | $31.9 million |
| Employees | 5 (3 on RocketReach) |
| Founded | 1997 |
| Phone | (919) 595-0400 |
| Fax | (919) 595-0401 |
| Technologies |
JavaScript,
HTML,
jQuery
+8 more
(view full list)
|
| Industry | Biotechnology Research, Business Services General, Biotechnology, Alphavirus, Business Services, Science and Engineering, Vaccine, Health Care, Medical |
| Competitors | Immatics, Intercell AG, THERAVECTYS, Transgene, Virometix AG |
| SIC | SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 325414 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies, NAICS Code 3254 Companies |
Looking for a particular AlphaVax employee's phone or email?
AlphaVax Questions
The AlphaVax annual revenue was $24 million in 2024.
3 people are employed at AlphaVax.
The NAICS codes for AlphaVax are [325414, 325, 32, 32541, 3254].
The SIC codes for AlphaVax are [283, 28].
Top AlphaVax Employees
Related Companies
